Today ABG Sundal Collier Equity Research sat down with AlzeCure Pharma's CEO Martin Jönsson to discuss the company's recent momentum and plans going forward. Watch the full interview here!
From clinical-stage pipeline to validated partnerships
AlzeCure Pharma is a Swedish pharmaceutical company developing a broad portfolio of small-molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain across its three research platforms NeuroRestore®, Alzstatin® and Painless. The company is listed on Nasdaq First North Premier Growth Market under the ticker "ALZCUR".
Brieftly about AlzeCure
Vision: To develop innovative small-molecule therapies that address the significant unmet medical needs in Alzheimer's disease and pain
Focus: Central nervous system disorders with a differentiated small-molecule approach
Platforms: NeuroRestore®, Alzstatin® and Painless
Recent momentum
Eli Lilly transaction — AlzeCure out-licensed its Alzheimer's candidate Alzstatin® to Eli Lilly in a deal with a total potential value exceeding USD 1 billion
QuantumCell transaction — AlzeCure announced a global out-licensing and collaboration agreement with Danish tech-enabled biotech QuantumCell ApS for its NeuroRestore® platform and lead candidate ACD856, with a total potential deal value exceeding USD 2.2 billion
Strong equity backing — QuantumCell is supported by a highly credible investor syndicate including Novo Holdings, Lundbeckfond Invest and Forbion
Oversubscribed Rights Issue — The company's SEK 30 million Rights Issue, which closed on June 30, was heavily oversubscribed at approximately 329 percent, reflecting strong investor interest
Remaining pipeline — With NeuroRestore® and Alzstatin® now out-licensed, AlzeCure retains its Painless platform, including ACD440 which has received positive FDA feedback for a registrational study
* ABG Sundal Collier is proud to have acted as financial advisor to AlzeCure in connection with the out-licensing deal with QuantumCell ApS and the Rights Issue and would like to congratulate AlzeCure on these important milestones.